For a 69‑kg adult with pancreatogenic (type 3c) diabetes and overnight glucose values of 351 mg/dL and 262 mg/dL who is currently taking insulin glargine (Lantus) 16 U daily and using an insulin‑to‑carbohydrate ratio of 1 U per 10 g carbohydrate with a medium correction factor, what should the insulin glargine dose and insulin‑to‑carbohydrate ratio be adjusted to?

Insulin Dose Adjustment for Pancreatogenic Diabetes with Severe Overnight Hyperglycemia

Increase Lantus to 24 units at bedtime and initiate rapid-acting insulin at 7 units before each meal (breakfast, lunch, dinner), while maintaining the 1:10 insulin-to-carbohydrate ratio and medium correction factor. This aggressive basal-bolus approach is essential because overnight glucose values of 351 and 262 mg/dL indicate profound basal insulin inadequacy, and pancreatogenic diabetes typically requires higher insulin doses due to both insulin and glucagon deficiency. 1, 2

Immediate Basal Insulin Adjustment

• Increase Lantus from 16 to 24 units (a 50% increase or approximately 8 units), administered at bedtime to target fasting glucose of 80–130 mg/dL. 1
• For a 69-kg patient with severe overnight hyperglycemia (>250 mg/dL), the current 16 units represents only 0.23 units/kg/day—far below the 0.3–0.5 units/kg/day recommended for severe hyperglycemia. 1
• Titrate basal insulin aggressively by 4 units every 3 days while fasting glucose remains ≥180 mg/dL, which applies to both overnight readings in this case. 1, 2
• The target basal dose for this patient should approach 0.35–0.5 units/kg/day (approximately 24–35 units) before considering further prandial intensification. 1

Initiation of Scheduled Prandial Insulin

• Start rapid-acting insulin (lispro, aspart, or glulisine) at 7 units before each of the three main meals (breakfast, lunch, dinner), calculated as approximately 10% of the anticipated basal dose of 24 units, rounded up for severe hyperglycemia. 1, 2
• Administer prandial insulin 0–15 minutes before meals to achieve optimal post-prandial control. 1
• Discontinue sliding-scale insulin as monotherapy; correction doses must supplement—not replace—scheduled basal and prandial insulin, as sliding-scale alone achieves target glucose in only ~38% of patients versus ~68% with basal-bolus therapy. 1, 2
• The 1:10 insulin-to-carbohydrate ratio should be maintained initially, with adjustments made only after observing a consistent pattern over ≥3 days. 1

Prandial Insulin Titration Protocol

• Increase each meal dose by 1–2 units every 3 days based on 2-hour post-prandial glucose readings, targeting post-prandial glucose <180 mg/dL. 1, 2
• If post-prandial glucose consistently exceeds 180 mg/dL after 3 days, increase that specific meal dose by 2 units. 1
• The medium correction factor should be applied in addition to the scheduled prandial dose when pre-meal glucose exceeds predefined thresholds (typically 2 units for >250 mg/dL, 4 units for >350 mg/dL). 1

Special Considerations for Pancreatogenic (Type 3c) Diabetes

• Pancreatogenic diabetes results from both insulin and glucagon deficiency, leading to greater glucose variability and increased insulin requirements compared to type 2 diabetes. 3, 4
• The primary pathophysiologic defect is insulin deficiency from "bystander" injury to islets from pancreatic fibrosis and cytokine-induced beta cell dysfunction. 3
• Patients with type 3c diabetes often require higher weight-based insulin doses (approaching 0.5–0.7 units/kg/day total) due to the combined hormonal deficiencies. 4
• Continuous glucose monitoring is essential for optimal management in pancreatogenic diabetes due to significant glucose variability and increased hypoglycemia risk from glucagon deficiency. 4

Critical Threshold Monitoring (Avoiding Over-Basalization)

• Stop basal insulin escalation when the dose approaches 0.5 units/kg/day (approximately 35 units for this 69-kg patient) without achieving fasting glucose targets; at that point, focus on intensifying prandial insulin rather than further basal increases. 1, 2
• Clinical signals of over-basalization include: basal dose >0.5 units/kg/day, bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia episodes, and high glucose variability. 1, 2
• For this patient, the bedtime-to-morning differential cannot be assessed without bedtime readings, but the severe overnight hyperglycemia (351 and 262 mg/dL) clearly indicates inadequate basal coverage rather than over-basalization. 1

Monitoring Requirements During Titration

• Check fasting glucose daily to guide basal insulin adjustments, targeting 80–130 mg/dL. 1, 2
• Measure pre-meal glucose before each meal to calculate correction doses using the medium correction factor. 1
• Obtain 2-hour post-prandial glucose after each meal to assess prandial insulin adequacy and guide dose titration. 1, 2
• Reassess the entire insulin regimen every 3 days during active titration. 1, 2
• Check for ketones (urine or blood) if glucose exceeds 300 mg/dL with symptoms such as nausea or vomiting, as pancreatogenic diabetes carries risk for ketoacidosis despite being classified as type 3c. 1, 4

Hypoglycemia Management (Critical in Pancreatogenic Diabetes)

• Treat any glucose <70 mg/dL immediately with 15 g of fast-acting carbohydrate, recheck in 15 minutes, and repeat if needed. 1, 2
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20% immediately before the next administration. 1, 2
• Glucagon deficiency in pancreatogenic diabetes increases hypoglycemia risk and may impair counter-regulatory responses, requiring more aggressive hypoglycemia prevention strategies. 3, 4
• Prescribe emergency glucagon for all patients with pancreatogenic diabetes due to the combined insulin and glucagon deficiency. 4

Expected Clinical Outcomes

• With properly implemented basal-bolus therapy at weight-based dosing, approximately 68% of patients achieve mean glucose <140 mg/dL, compared with only 38% using sliding-scale insulin alone. 1, 2
• The anticipated total daily insulin dose for this patient should reach 0.5–0.7 units/kg/day (approximately 35–48 units total) once fully titrated, split roughly 50% basal and 50% prandial. 1, 4
• HbA1c reduction of 2–3% is achievable within 3–6 months with intensive basal-bolus titration in patients with severe hyperglycemia. 1, 2
• Properly executed basal-bolus regimens do not increase overall hypoglycemia incidence compared with inadequate sliding-scale approaches when titrated according to protocol. 1, 2

Common Pitfalls to Avoid

• Do not delay aggressive basal insulin titration when overnight glucose consistently exceeds 250 mg/dL; prolonged hyperglycemia increases complication risk. 1, 2
• Do not rely solely on correction (sliding-scale) insulin without scheduled basal and prandial doses; this reactive strategy is condemned by major diabetes guidelines and causes dangerous glucose fluctuations. 1, 2
• Do not continue escalating basal insulin beyond 0.5–1.0 units/kg/day without addressing post-prandial hyperglycemia, as this leads to over-basalization with increased hypoglycemia risk. 1, 2
• Never use rapid-acting insulin at bedtime as a sole correction dose, as this markedly raises nocturnal hypoglycemia risk—particularly dangerous in pancreatogenic diabetes with glucagon deficiency. 1, 2
• Do not assume pancreatogenic diabetes behaves like type 2 diabetes; the combined insulin and glucagon deficiency requires more aggressive insulin therapy and closer monitoring. 3, 4